Search results for " Fatty liver"

showing 10 items of 338 documents

Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease

2015

Article

MaleMagnetic Resonance Spectroscopymedicine.medical_treatmentBiopsyAdipose tissuelcsh:MedicineFats0302 clinical medicineNon-alcoholic Fatty Liver DiseaseMetabolitesTerveystiede - Health care scienceSkeletal musclesAmino Acidslcsh:ScienceNon-U.S. Gov'tchemistry.chemical_classification0303 health sciencesMultidisciplinaryResearch Support Non-U.S. Gov'tFatty liverFatty AcidsrasvamaksaMiddle Aged3. Good healthAmino acidmedicine.anatomical_structureAdipose TissueLiverFemaleResearch Articlemedicine.medical_specialtyAdipose tissue030209 endocrinology & metabolismamino acid metabolismBiologyResearch Support03 medical and health sciencesInsulin resistanceInternal medicineFatty livermedicineJournal ArticleHumansObesityFatty acids030304 developmental biologyfatty liverCatabolismInsulinta1184lcsh:RFatty acidSkeletal muscleta3121medicine.diseaseEndocrinologychemistrylcsh:QGene expression
researchProduct

Dietary Inflammatory Index and liver status in subjects with different adiposity levels within the PREDIMED trial.

2018

Summary Background & aims To assess the possible association between a validated Dietary Inflammatory Index (DII) and specific dietary components with suitable non-invasive markers of liver status in overweight and obese subjects within the PREDIMED study. Methods A cross-sectional study encompassing 794 randomized overweight and obese participants (mean ± SD age: 67.0 ± 5.0 y, 55% females) from the PREDIMED (PREvencion con DIeta MEDiterranea) trial was conducted. DII is a validated tool evaluating the effect of diet on six inflammatory biomarkers (IL-1b, IL-4, IL-6, IL-10, TNF-α and C-reactive protein). Furthermore, a validated 137-item food-frequency-questionnaire was used to obtain the i…

MaleMediterranean dietPhysiologyDiseaseFetge -- MalaltiesOverweightCritical Care and Intensive Care MedicineDiet Mediterranean0302 clinical medicineNon-alcoholic Fatty Liver DiseaseSurveys and QuestionnairesAdiposityNutrition and DieteticsMalalties del fetgeFatty liverMiddle AgedInflamacióDiet RecordsC-Reactive ProteinLiver030220 oncology & carcinogenesisObesitatDieta030211 gastroenterology & hepatologyFemalemedicine.symptommedicine.medical_specialtyInflammation03 medical and health sciencesInternal medicineNAFLDmedicineHumansObesityLiver diseasesAgedInflammationbusiness.industryTumor Necrosis Factor-alphaInterleukinsAdipose tissuesAnthropometryOverweightmedicine.diseasePredimedObesityDietTeixit adipósEndocrinologyCross-Sectional StudiesPatient CompliancebusinessBiomarkers
researchProduct

Altilix

2019

The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix® (26 men and 24 women, mean age 63 ± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endot…

MaleMetabolic Syndromecynaranon-alcoholic fatty liver diseaseMiddle AgedArticlecardiovascular diseasesdietary supplementsDouble-Blind MethodLivertype 2Risk Factorsdiabetes mellitusHumansFemaleChlorogenic AcidLuteolinBiomarkersAgedNutrients
researchProduct

Non-alcoholic fatty liver disease and the development of nephrolithiasis: A cohort study.

2017

Background Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation or precursor of metabolic syndrome, may increase nephrolithiasis, a renal manifestation of insulin resistance, but the prospective association between NAFLD and incident nephrolithiasis has not been evaluated. We examined the association of NAFLD with the development of nephrolithiasis in a large cohort of Korean men and women. Methods We performed a cohort study of 208,578 Korean adults who underwent a health checkup examination between January 2002 and December 2014 and were followed-up annually or biennially through December 2014. NAFLD was defined as the presence of fatty liver in the absence of excessive alco…

MalePhysiology030232 urology & nephrologylcsh:MedicineBlood PressureGastroenterologyVascular MedicineBody Mass IndexCohort Studies0302 clinical medicineEndocrinologyNon-alcoholic Fatty Liver DiseaseMedicine and Health Scienceslcsh:ScienceMultidisciplinaryAlcohol ConsumptionIncidence (epidemiology)Liver DiseasesHazard ratioFatty liverMiddle AgedChemistryPhysiological ParametersResearch DesignHypertensionPhysical Sciences030211 gastroenterology & hepatologyFemaleCohort studyResearch ArticleAdultmedicine.medical_specialtyEndocrine DisordersGastroenterology and HepatologyNephrolithiasisResearch and Analysis Methods03 medical and health sciencesInsulin resistanceInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansNutritionEndocrine Physiologybusiness.industrylcsh:RBody WeightChemical Compoundsnutritional and metabolic diseasesBiology and Life Sciencesmedicine.diseasedigestive system diseasesDietUric AcidFatty LiverMetabolic Disorderslcsh:QMetabolic syndromeInsulin ResistancebusinessBody mass indexAcidsPloS one
researchProduct

Recent insights into the relationship between inflammatory liver diseases and atherosclerosis.

2011

Atherosclerosis is a dynamic process in the human body. Many studies have evaluated atherosclerosis and its relationship with other systems in the body. Our perception of its pathogenesis is evolving with the introduction of new players in the game. It is no longer possible to consider the atherosclerosis as an independent process, unaffected by the liver and its function. Although several tasks performed by the liver, such as lipid metabolism, have been implicated in the pathogenesis of atherosclerosis, the role of other disorders of the liver (autoimmune diseases, viral hepatitis, and cirrhosis) are not fully understood. In this review, the most commonly encountered inflammatory liver di…

MaleRiskHepatitis B virusCirrhosisInflammationHepacivirusBiologyGeneral Biochemistry Genetics and Molecular BiologyAutoimmune DiseasesHepatitisPathogenesisFibrosisPrevalencemedicineHumansInflammationHepatitisCholestasisLiver DiseasesResearchFatty liverLipid metabolismGeneral MedicineAtherosclerosismedicine.diseasehepatitis B hepatitis C hepatitis A inflammation fatty liver atherosclerosisFibrosisFatty LiverLiverImmunologyFemalemedicine.symptomViral hepatitis
researchProduct

Under-prescription of statins in patients with non-alcoholic fatty liver disease

2017

Abstract Background and Aim Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with high cardiovascular risk. Management of dyslipidaemia plays a pivotal role in the prevention of CV events and statins have proved to be safe in these patients. However, in everyday clinical practice statin prescription is sometimes limited because of the concern of physicians about side-effects. The aim of the study was to investigate if the presence of NAFLD affects the prescription of lipid-lowering treatment in a large series of patients with cardio-metabolic disorders. Methods and Results Cardiovascular risk and LDL-C targets were defined according to ESC/EAS Guidelines in 605 conse…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Disease030204 cardiovascular system & hematologyEndocrinology0302 clinical medicineDrug PrescriptionNon-alcoholic Fatty Liver DiseaseRisk FactorsCardiovascular DiseaseNutrition and DieteticPractice Patterns Physicians'Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedDiabetes and MetabolismCardiovascular DiseasesPractice Guidelines as TopicCohortUnder-prescriptionFemalelipids (amino acids peptides and proteins)030211 gastroenterology & hepatologyGuideline AdherenceCardiology and Cardiovascular MedicineHumanAdultCardiovascular risk; Non-alcoholic fatty liver disease; Statins; Under-prescription; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyStatinmedicine.drug_classContext (language use)Health Services MisuseDrug Prescriptions03 medical and health sciencesInternal medicinemedicineHumansMedical prescriptionAgedDyslipidemiasCross-Sectional Studiebusiness.industryRisk FactorStatinsStatinnutritional and metabolic diseasesNon alcoholicBiomarkerCholesterol LDLCardiovascular riskmedicine.diseaseCross-Sectional StudiesDyslipidemiaPhysical therapyHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profilebusinessBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Nonalcoholic fatty liver and metabolic syndrome in Italy: Results from a multicentric study of the Italian Arteriosclerosis society

2013

Nonalcoholic fatty liver disease (NAFLD) is associated with all the components of metabolic syndrome (MS) and might to be considered an additional component of MS itself. The Italian Society for the Study of Atherosclerosis (SISA) in 2005 started a research project aimed to study the NAFLD, using ultrasound (US), in nondiabetic MS subjects matching at least one of the ATP III criteria for HDL-C or triglycerides [TG]. Prevalence of US-NAFLD and its associated risk factors and prevalence of hypertransaminasemia and its possible determinants were evaluated. NAFLD prevalence was 0.78. Men with steatosis compared to men without steatosis were younger (P < 0.05) with higher TG (P < 0.03), homeost…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismNonalcoholic fatty liverSex FactorSettore MED/13 - EndocrinologiaBody Mass IndexEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseAtherosclerosis; Metabolic Syndrome X; Sex Factors; Humans; Lipids; Aged; Fatty Liver; Non-alcoholic Fatty Liver Disease; Body Mass Index; Italy; Logistic Models; Risk Factors; Liver; Middle Aged; Female; MaleUltrasonographyMulticentric studyMetabolic Syndrome XFatty liverGeneral MedicineArteriosclerosisLipidMiddle AgedLipidsMetabolic syndromeDiabetes and MetabolismItalyLiverAtherosclerosiFemaleHumanmedicine.medical_specialtyLogistic ModelNonalcoholic fatty liver Metabolic syndrome Lipids Multicentric studyInsulin resistanceSex FactorsDiabetes mellitusInternal medicinemedicineInternal MedicineHumansLipids; Metabolic syndrome; Multicentric study; Nonalcoholic fatty liver; Aged; Body Mass Index; Fatty Liver; Female; Humans; Italy; Lipids; Liver; Logistic Models; Male; Metabolic Syndrome X; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Sex Factors; Atherosclerosis; Endocrinology; Internal Medicine; Endocrinology Diabetes and MetabolismAgedbusiness.industryRisk Factornutritional and metabolic diseasesAmbientalemedicine.diseaseAtherosclerosisFatty LiverEndocrinologyLogistic ModelsMetabolic syndromeSteatosisbusinessBody mass index
researchProduct

Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: The ITA.LI.CA database

2021

BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort.MethodsWe analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC.ResultsMAFLD was diagnosed in the majority of patients w…

MaleSettore MED/12 - GastroenterologiaCarcinoma HepatocellularLiver Neoplasmsnonalcoholic steatohepatitis.Gastroenterologyhepatocellular carcinomadigestive system diseaseshepatocellular carcinoma; nonalcoholic steatohepatitisNon-alcoholic Fatty Liver DiseaseRisk FactorsHumansnonalcoholic steatohepatitisneoplasms
researchProduct

Reply

2015

MaleSettore MED/12 - GastroenterologiaCarotid Artery DiseaseHepatologybusiness.industryPharmacologyLipoproteins VLDLMembrane proteinNon-alcoholic Fatty Liver DiseaseMedicineFemalebusinessMembrane ProteinVldl metabolismHuman
researchProduct

Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease.

2015

The small heterodimer partner (SHP) (NR0B2) is an atypical nuclear receptor that lacks a DNA-binding domain. It interacts with and inhibits many transcription factors, affecting key metabolic processes, including bile acid, cholesterol, fatty acid, and drug metabolism. Our aim was to determine the influence of steatotic drugs and nonalcoholic fatty liver disease (NAFLD) on SHP expression and investigate the potential mechanisms. SHP was found to be repressed by steatotic drugs (valproate, doxycycline, tetracycline, and cyclosporin A) in cultured hepatic cells and the livers of different animal models of NAFLD: iatrogenic (tetracycline-treated rats), genetic (glycine N-methyltransferase-defi…

MaleTranscription GeneticThiazepinesResponse elementReceptors Cytoplasmic and NuclearBiologyMiceNon-alcoholic Fatty Liver DiseaseCyclosporin amedicineCCAAT-Enhancer-Binding Protein-alphaAnimalsHumansProtein kinase APromoter Regions GeneticTranscription factorCells CulturedPharmacologyMitogen-Activated Protein Kinase 1KinaseValproic AcidFatty liverTetracyclinemedicine.diseaseFatty LiverDoxycyclineCancer researchSmall heterodimer partnerCyclosporineMolecular MedicineSignal transductionSignal TransductionMolecular pharmacology
researchProduct